ERO1A and neoplasm: For example, inhibition of ERO1A/IRE1α in tumors might have a synergetic anti-tumor effect with immune checkpoint blockade by turning the tumor immunogenic and removing immune-suppressive signals, thereby restoring the anti-tumor capacity of the T cells in tumor hosts.